20 research outputs found
Impact on Prehospital Delay of a Stroke Preparedness Campaign: A SW-RCT (Stepped-Wedge Cluster Randomized Controlled Trial)
Background and Purpose—Public campaigns to increase stroke preparedness have been tested in different contexts,
showing contradictory results. We evaluated the effectiveness of a stroke campaign, designed specifically for the Italian
population in reducing prehospital delay.
Methods—According to an SW-RCT (Stepped-Wedge Cluster Randomized Controlled Trial) design, the campaign was
launched in 4 provinces in the northern part of the region Emilia Romagna at 3-month intervals in randomized sequence.
The units of analysis were the patients admitted to hospital, with stroke and transient ischemic attack, over a time period
of 15 months, beginning 3 months before the intervention was launched in the first province to allow for baseline data
collection. The proportion of early arrivals (within 2 hours of symptom onset) was the primary outcome. Thrombolysis
rate and some behavioral end points were the secondary outcomes. Data were analyzed using a fixed-effect model,
adjusting for cluster and time trends.
Results—We enrolled 1622 patients, 912 exposed and 710 nonexposed to the campaign. The proportion of early access
was nonsignificantly lower in exposed patients (354 [38.8%] versus 315 [44.4%]; adjusted odds ratio, 0.81; 95%
confidence interval, 0.60–1.08; P=0.15). As for secondary end points, an increase was found for stroke recognition, which
approximated but did not reach statistical significance (P=0.07).
Conclusions—Our campaign was not effective in reducing prehospital delay. Even if some limitations of the intervention,
mainly in terms of duration, are taken into account, our study demonstrates that new communication strategies should be
tested before large-scale implementation.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01881152
Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes.
Background In patients with acute ischemic stroke and atrial fibrillation, early anticoagulation prevents ischemic recurrence but with the risk of hemorrhagic transformation ( HT ). The aims of this study were to evaluate in consecutive patients with acute stroke and atrial fibrillation (1) the incidence of early HT, (2) the time to initiation of anticoagulation in patients with HT , (3) the association of HT with ischemic recurrences, and (4) the association of HT with clinical outcome at 90 days. Methods and Results HT was diagnosed by a second brain computed tomographic scan performed 24 to 72 hours after stroke onset. The incidence of ischemic recurrences as well as mortality or disability (modified Rankin Scale scores >2) were evaluated at 90 days. Ischemic recurrences were the composite of ischemic stroke, transient ischemic attack, or systemic embolism. Among the 2183 patients included in the study, 241 (11.0%) had HT . Patients with and without HT initiated anticoagulant therapy after a mean 23.3 and 11.6 days, respectively, from index stroke. At 90 days, 4.6% (95% confidence interval, 2.3-8.0) of the patients with HT had ischemic recurrences compared with 4.9% (95% confidence interval, 4.0-6.0) of those without HT ; 53.1% of patients with HT were deceased or disabled compared with 35.8% of those without HT . On multivariable analysis, HT was associated with mortality or disability (odds ratio, 1.71; 95% confidence interval, 1.24-2.35). Conclusions In patients with HT , anticoagulation was initiated about 12 days later than patients without HT . This delay was not associated with increased detection of ischemic recurrence. HT was associated with increased mortality or disability
Sonography of the optic nerve sheath beyond the hyperacute stage of intracerebral hemorrhage.
PURPOSE: To evaluate the feasibility and utility of serial measuring of the optic nerve sheath diameter beyond the hyperacute and acute stage of intracerebral hemorrhage (ICH).
METHODS: Four patients with extensive ICH in the left basal ganglia were followed using ultrasound (US) and cerebral CT scans.
RESULTS: Optic nerve sheath diameter values assessed beyond the acute stage of ICH showed a high correlation (\u3c1 = 0.84, p = 0.0022) with midline shift of the third ventricle seen on CT scans.
CONCLUSIONS: Optic nerve sonography can be useful to evaluate patients with extensive ICH beyond the acute stage and help monitoring clinical evolution in these patients, when ICP monitoring is not feasible
Development of an education campaign to reduce delays in pre-hospital response to stroke
Background: Systematic reviews call for well-designed trials with clearly described intervention components to
support the effectiveness of educational campaigns to reduce patient delay in stroke presentation. We herein
describe the systematic development process of a campaign aimed to increase stroke awareness and preparedness.
Methods: Campaign development followed Intervention Mapping (IM), a theory- and evidence-based tool, and was
articulated in two phases: needs assessment and intervention development. In phase 1, two cross-sectional surveys
were performed, one aiming to measure stroke awareness in the target population and the other to analyze the
behavioral determinants of prehospital delay. In phase 2, a matrix of proximal program objectives was developed,
theory-based intervention methods and practical strategies were selected and program components and materials
produced.
Results: In phase 1, the survey on 202 citizens highlighted underestimation of symptom severity, as in only 44% of
stroke situations respondents would choose to call the emergency service (EMS). In the survey on 393 consecutive
patients, 55% presented over 2 hours after symptom onset; major determinants were deciding to call the general
practitioner first and the reaction of the first person the patient called. In phase 2, adult individuals were identified
as the target of the intervention, both as potential “patients” and witnesses of stroke. The low educational level
found in the patient survey called for a narrative approach in cartoon form. The family setting was chosen for the
message because 42% of patients who presented within 2 hours had been advised by a family member to call
EMS. To act on people’s tendency to view stroke as an untreatable disease, it was decided to avoid fear-arousal
appeals and use a positive message providing instructions and hope. Focus groups were used to test educational
products and identify the most suitable sites for message dissemination.
Conclusions: The IM approach allowed to develop a stroke campaign integrating theories, scientific evidence and
information collected from the target population, and enabled to provide clear explanations for the reasons behind
key decisions during the intervention development process.
Trial registration: NCT01881152. Retrospectively registered June 7 2013
Keywords: Stroke, Public campaign, Pre-hospital delay, Media, Cartoon, Intervention mappin
Association Between Migraine and Cervical Artery Dissection: The Italian Project on Stroke in Young Adults.
IMPORTANCE Although sparse observational studies have suggested a link between migraine
and cervical artery dissection (CEAD), any association between the 2 disorders is still
unconfirmed. This lack of a definitive conclusion might have implications in understanding
the pathogenesis of both conditions and the complex relationship between migraine and
ischemic stroke (IS).
OBJECTIVE To investigate whether a history of migraine and its subtypes is associated with
the occurrence of CEAD.
DESIGN, SETTING, AND PARTICIPANTS A prospective cohort study of consecutive patients
aged 18 to 45 years with first-ever acute ischemic stroke enrolled in the multicenter Italian
Project on Stroke in Young Adults was conducted between January 1, 2000, and June 30,
2015. In a case-control design, the study assessed whether the frequency of migraine and its
subtypes (presence or absence of an aura) differs between patients whose IS was due to
CEAD (CEAD IS) and those whose IS was due to a cause other than CEAD (non-CEAD IS) and
compared the characteristics of patients with CEAD IS with and without migraine.
MAIN OUTCOMES AND MEASURES Frequency of migraine and its subtypes in patients with
CEAD IS vs non-CEAD IS.
RESULTS Of the 2485 patients (mean [SD] age, 36.8 [7.1] years; women, 1163 [46.8%])
included in the registry, 334 (13.4%) had CEAD IS and 2151 (86.6%) had non-CEAD IS.
Migraine was more common in the CEAD IS group (103 [30.8%] vs 525 [24.4%], P = .01), and
the difference was mainly due to migraine without aura (80 [24.0%] vs 335 [15.6%],
P < .001). Compared with migraine with aura, migraine without aura was independently
associated with CEAD IS (OR, 1.74; 95%CI, 1.30-2.33). The strength of this association was
higher in men (OR, 1.99; 95%CI, 1.31-3.04) and in patients 39.0 years or younger (OR, 1.82;
95%CI, 1.22-2.71). The risk factor profile was similar in migrainous and non-migrainous
patients with CEAD IS (eg, hypertension, 20 [19.4%] vs 57 [24.7%], P = .29; diabetes, 1 [1.0%]
vs 3 [1.3%], P > .99).
CONCLUSIONS AND RELEVANCE In patients with IS aged 18 to 45 years, migraine, especially
migraine without aura, is consistently associated with CEAD. This finding suggests common
features and warrants further analyses to elucidate the underlying biologic mechanisms
GEN-O-MA project: an Italian network studying clinical course and pathogenic pathways of moyamoya disease—study protocol and preliminary results
Background: GENetics of mOyaMoyA (GEN-O-MA) project is a multicenter observational study implemented in Italy aimed at creating a network of centers involved in moyamoya angiopathy (MA) care and research and at collecting a large series and bio-repository of MA patients, finally aimed at describing the disease phenotype and clinical course as well as at identifying biological or cellular markers for disease progression. The present paper resumes the most important study methodological issues and preliminary results. Methods: Nineteen centers are participating to the study. Patients with both bilateral and unilateral radiologically defined MA are included in the study. For each patient, detailed demographic and clinical as well as neuroimaging data are being collected. When available, biological samples (blood, DNA, CSF, middle cerebral artery samples) are being also collected for biological and cellular studies. Results: Ninety-eight patients (age of onset mean \ub1 SD 35.5 \ub1 19.6 years; 68.4% females) have been collected so far. 65.3% of patients presented ischemic (50%) and haemorrhagic (15.3%) stroke. A higher female predominance concomitantly with a similar age of onset and clinical features to what was reported in previous studies on Western patients has been confirmed. Conclusion: An accurate and detailed clinical and neuroimaging classification represents the best strategy to provide the characterization of the disease phenotype and clinical course. The collection of a large number of biological samples will permit the identification of biological markers and genetic factors associated with the disease susceptibility in Italy
Intravenous Thrombolysis in Patients With Ischemic Stroke Aged ≥90 Years: A Cohort Study From the TRISP Collaboration
Background: The probability to receive intravenous thrombolysis (IVT) for treatment of acute ischemic stroke declines with increasing age and is consequently the lowest in very elderly patients. Safety concerns likely influence individual IVT treatment decisions. Using data from a large IVT registry, we aimed to provide more evidence on safety of IVT in the very elderly. Methods: In this prospective multicenter study from the TRISP (Thrombolysis in Ischemic Stroke Patients) registry, we compared patients ≥90 years with those <90 years using symptomatic intracranial hemorrhage (ECASS [European Cooperative Acute Stroke Study]-II criteria), death, and poor functional outcome in survivors (modified Rankin Scale score 3-5 for patients with prestroke modified Rankin Scale score ≤2 and modified Rankin Scale score 4-5 for patients prestroke modified Rankin Scale ≥3) at 3 months as outcomes. We calculated adjusted odds ratio with 95% CI using logistic regression models. Results: Of 16 974 eligible patients, 976 (5.7%) were ≥90 years. Patients ≥90 years had higher median National Institutes of Health Stroke Scale on admission (12 versus 8) and were more often dependent prior to the index stroke (prestroke modified Rankin Scale score of ≥3; 45.2% versus 7.4%). Occurrence of symptomatic intracranial hemorrhage (5.7% versus 4.4%, odds ratioadjusted 1.14 [0.83-1.57]) did not differ significantly between both groups. However, the probability of death (odds ratioadjusted 3.77 [3.14-4.53]) and poor functional outcome (odds ratioadjusted 2.63 [2.13-3.25]) was higher in patients aged ≥90 years. Results for the sample of centenarians (n=21) were similar. Conclusions: The probability of symptomatic intracranial hemorrhage after IVT in very elderly patients with stroke did not exceed that of their younger counterparts. The higher probability of death and poor functional outcome during follow-up in the very elderly seems not to be related to IVT treatment. Very high age itself should not be a reason to withhold IVT. © 2022 American Heart Association, Inc
Hemorrhagic transformation in patients with acute ischemic stroke and atrial fibrillation: Time to initiation of oral anticoagulant therapy and outcomes
Background—In patients with acute ischemic stroke and atrial fibrillation, early anticoagulation prevents ischemic recurrence but with the risk of hemorrhagic transformation (HT). The aims of this study were to evaluate in consecutive patients with acute stroke and atrial fibrillation (1) the incidence of early HT, (2) the time to initiation of anticoagulation in patients with HT, (3) the association of HT with ischemic recurrences, and (4) the association of HT with clinical outcome at 90 days. Methods and Results—HT was diagnosed by a second brain computed tomographic scan performed 24 to 72 hours after stroke onset. The incidence of ischemic recurrences as well as mortality or disability (modified Rankin Scale scores >2) were evaluated at 90 days. Ischemic recurrences were the composite of ischemic stroke, transient ischemic attack, or systemic embolism. Among the 2183 patients included in the study, 241 (11.0%) had HT. Patients with and without HT initiated anticoagulant therapy after a mean 23.3 and 11.6 days, respectively, from index stroke. At 90 days, 4.6% (95% confidence interval, 2.3-8.0) of the patients with HT had ischemic recurrences compared with 4.9% (95% confidence interval, 4.0-6.0) of those without HT; 53.1% of patients with HT were deceased or disabled compared with 35.8% of those without HT. On multivariable analysis, HT was associated with mortality or disability (odds ratio, 1.71; 95% confidence interval, 1.24-2.35). Conclusions—In patients with HT, anticoagulation was initiated about 12 days later than patients without HT. This delay was not associated with increased detection of ischemic recurrence. HT was associated with increased mortality or disability. © 2018 The Authors
Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with Non-Vitamin-K oral anticoagulants (RAF-NOACs) Study
Background--The optimal timing to administer non-vitamin K oral anticoagulants (NOACs) in patients with acute ischemic stroke and atrial fibrillation is unclear. This prospective observational multicenter study evaluated the rates of early recurrence and major bleeding (within90 days)and their timing in patients with acute ischemic stroke and atrial fibrillation who received NOACs for secondary prevention. Methods and Results--Recurrence was defined as the composite of ischemic stroke, transient ischemic attack, and symptomatic systemic embolism, and major bleeding was defined as symptomatic cerebral and major extracranial bleeding. For the analysis, 1127 patients were eligible: 381 (33.8%) were treated with dabigatran, 366 (32.5%) with rivaroxaban, and 380 (33.7%) with apixaban. Patients who received dabigatran were younger and had lower admission National Institutes of Health Stroke Scale score and less commonly had a CHA2DS2-VASc score > 4 and less reduced renal function. Thirty-two patients (2.8%) had early recurrence, and 27 (2.4%) had major bleeding. The rates of early recurrence and major bleeding were, respectively, 1.8% and 0.5% in patients receiving dabigatran, 1.6% and 2.5% in those receiving rivaroxaban, and 4.0% and 2.9% in those receiving apixaban. Patients who initiated NOACs within 2 days after acute stroke had a composite rate of recurrence and major bleeding of 12.4%; composite rates were 2.1% for those who initiated NOACs between 3 and 14 days and 9.1% for those who initiated > 14 days after acute stroke. Conclusions--In patients with acute ischemic stroke and atrial fibrillation, treatment with NOACs was associated with a combined 5% rate of ischemic embolic recurrence and severe bleeding within 90 days. © 2017 The Authors
Causes and Risk Factors of Cerebral Ischemic Events in Patients with Atrial Fibrillation Treated with Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention: The RENo Study
Background and Purpose-Despite treatment with oral anticoagulants, patients with nonvalvular atrial fibrillation (AF) may experience ischemic cerebrovascular events. The aims of this case-control study in patients with AF were to identify the pathogenesis of and the risk factors for cerebrovascular ischemic events occurring during non-Vitamin K antagonist oral anticoagulants (NOACs) therapy for stroke prevention. Methods-Cases were consecutive patients with AF who had acute cerebrovascular ischemic events during NOAC treatment. Controls were consecutive patients with AF who did not have cerebrovascular events during NOACs treatment. Results-Overall, 713 cases (641 ischemic strokes and 72 transient ischemic attacks; median age, 80.0 years; interquartile range, 12; median National Institutes of Health Stroke Scale on admission, 6.0; interquartile range, 10) and 700 controls (median age, 72.0 years; interquartile range, 8) were included in the study. Recurrent stroke was classified as cardioembolic in 455 cases (63.9%) according to the A-S-C-O-D (A, atherosclerosis; S, small vessel disease; C, cardiac pathology; O, other causes; D, dissection) classification. On multivariable analysis, off-label low dose of NOACs (odds ratio [OR], 3.18; 95% CI, 1.95-5.85), atrial enlargement (OR, 6.64; 95% CI, 4.63-9.52), hyperlipidemia (OR, 2.40; 95% CI, 1.83-3.16), and CHA2DS2-VASc score (OR, 1.72 for each point increase; 95% CI, 1.58-1.88) were associated with ischemic events. Among the CHA2DS2-VASc components, age was older and presence of diabetes mellitus, congestive heart failure, and history of stroke or transient ischemic attack more common in patients who had acute cerebrovascular ischemic events. Paroxysmal AF was inversely associated with ischemic events (OR, 0.45; 95% CI, 0.33-0.61). Conclusions-In patients with AF treated with NOACs who had a cerebrovascular event, mostly but not exclusively of cardioembolic pathogenesis, off-label low dose, atrial enlargement, hyperlipidemia, and high CHA2DS2-VASc score were associated with increased risk of cerebrovascular events. © 2019 American Heart Association, Inc